Trial · NCT00371345
Results by group186
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 186
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Objective Response | Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib | 0 | participants | ||
| Number of Participants With Objective Response | Her2/Neu-amplified Tumor, 100 mg BID | 1 | participants | ||
| Number of Participants With Objective Response | ER and/or PgR Positive Tumor, 70 mg BID Dasatinib | 1 | participants | ||
| Number of Participants With Objective Response | ER and/or PgR Positive Tumor, 100 mg BID Dasatinib | 1 | participants | ||
| Percentage of Participants With Objective Response | Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib | 0 | 95% Confidence Interval 0 to 0 | percentage of participants | |
| Percentage of Participants With Objective Response | Her2/Neu-amplified Tumor, 100 mg BID Dasatinib | 11.11 | 95% Confidence Interval 0.28 to 48.25 | percentage of participants | |
| Percentage of Participants With Objective Response | ER and/or PgR Positive Tumor, 70 mg BID Dasatinib | 3.23 | 95% Confidence Interval 0.08 to 16.70 | percentage of participants | |
| Percentage of Participants With Objective Response | ER and/or PgR Positive Tumor, 100 mg BID Dasatinib | 7.14 | 95% Confidence Interval 0.18 to 33.87 | percentage of participants | |
| Percentage of Participants With Objective Response | All Response-evaluable Participants | 4.35 | 95% Confidence Interval 0.91 to 12.18 | percentage of participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib | Participants with CR | 0 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | Her2/Neu-amplified Tumor, 100 mg BID Dasatinib | Participants with CR | 0 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | ER and/or PgR Positive Tumor, 70 mg BID Dasatinib | Participants with CR | 0 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | ER and/or PgR Positive Tumor, 100 mg BID Dasatinib | Participants with CR | 0 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib | Participants with unconfirmed PR (uCR) | 0 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | Her2/Neu-amplified Tumor, 100 mg BID Dasatinib | Participants with unconfirmed PR (uCR) | 0 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | ER and/or PgR Positive Tumor, 70 mg BID Dasatinib | Participants with unconfirmed PR (uCR) | 1 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | ER and/or PgR Positive Tumor, 100 mg BID Dasatinib | Participants with unconfirmed PR (uCR) | 0 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib | Participants with PR | 0 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | Her2/Neu-amplified Tumor, 100 mg BID Dasatinib | Participants with PR | 1 | participants | |
| Number of Response-evaluable Participants With Disease Control (DCR) | ER and/or PgR Positive Tumor, 70 mg BID Dasatinib | Participants with PR | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00371345/results